by Angela C. H. McDonald | Sep 11, 2012
You don’t have to follow pharmaceutical industry news to know that this summer has been a disappointing one for Alzheimer’s research. Many major media outlets covered the failure of potential Alzheimer’s drug bapineuzumab (Pfizer/Johnson & Johnson) in Phase II/III...
by Holly Wobma | Aug 22, 2012
With over 34 million people living with HIV, of which only the fortunate have continual access to life-saving anti-retroviral drugs, it comes as no surprise that the recent media announcement of a potential “cure” for HIV went rapidly…well…viral. The excitement...
by David Kent | May 24, 2012
As a basic researcher in stem cell biology, one of my biggest fears is moving too quickly with cell therapies that involve primitive, still largely mysterious, cell populations. At the World Stem Cells & Regenerative Medicine Congress meeting this week, I felt...
by David Kent | May 22, 2012
You might expect this article to be about creating skin grafts for burn victims or something of that ilk. Instead though, it concerns the complicated process of taking a scientific discovery in regenerative medicine and bringing that discovery through clinical trials...
by Paul Krzyzanowski | May 22, 2012
Many readers may already have heard of Health Canada’s approval of Osiris’ Prochymal, a mesenchymal stem cell treatment for severe cases of pediatric Graft versus Host Disease (GvHD), with plenty of coverage circulating around the web. GvHD is a disease where...
by Paul Krzyzanowski | May 4, 2012
Commercialization plenary summary: part 3 of 4 On day two (May 1) of the Till and McCulloch Meetings, Dr. Emily Culme-Seymour from the London Regenerative Medicine Network introduced work that leverages previous clinical trial information to support future cell...
Comments